Xenetic Biosciences
XBIO
7 hedge funds and large institutions have $79.4K invested in Xenetic Biosciences in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
1.28% less ownership
Funds ownership: 2.41% → 1.13% (-1.3%)
22% less funds holding
Funds holding: 9 → 7 (-2)
34% less capital invested
Capital invested by funds: $120K → $79.4K (-$41K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$45.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$85K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$17K |
| 3 |
NC
NewSquare Capital
Newtown Square,
Pennsylvania
|
-$85 |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$25 |
| 5 |
Wells Fargo
San Francisco,
California
|
-$4 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $53.8K | +$45.9K | +10,998 | New |
|
|
SPIA
2
Steward Partners Investment Advisory
New York
| $9.31K | – | – | – |
|
|
JEST
3
JTC Employer Solutions Trustee
St Helier,
Jersey
| $8K | – | – | – |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $6.78K | +$3.19K | +763 | +123% |
|
5
Morgan Stanley
New York
| $1.45K | – | – | – |
|
|
6
Wells Fargo
San Francisco,
California
| $49 | -$4 | -1 | -9% |
|
|
7
Fidelity Investments
Boston,
Massachusetts
| $5 | -$25 | -6 | -86% |
|
|
8
Renaissance Technologies
New York
| – | -$85K | -25,782 | Closed |
|
|
9
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$17K | -5,300 | Closed |
|
|
NC
10
NewSquare Capital
Newtown Square,
Pennsylvania
| – | -$85 | -26 | Closed |
|
XBIO Hedge Fund Activity: Q3 2023 in Review
7 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q3 2023, worth a combined $79.4K — down 34% from $120K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of XBIO and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $45.9K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $85K sold.
- 7 institutional investors held Xenetic Biosciences (XBIO) as of Q3 2023, down from 9 in Q2 2023.
- Funds reported $79.4K of Xenetic Biosciences stock for Q3 2023, down 34% quarter-over-quarter.
- 1 fund opened new Xenetic Biosciences positions in Q3 2023 and 3 closed out, a net change of -2 holders.
- The largest Xenetic Biosciences buyer in Q3 2023 was Geode Capital Management, an estimated $45.9K added.
- The largest Xenetic Biosciences seller in Q3 2023 was Renaissance Technologies, an estimated $85K sold.
Based on aggregated 13F filings for Q3 2023.